US FDA Grants Approval for Teva Pharmaceuticals' Generic Obesity Medication
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 28 2025
0mins
Source: Reuters
FDA Approval: The U.S. Food and Drug Administration has approved Teva Pharmaceuticals' generic version of Novo Nordisk's weight-loss drug, Saxenda.
Drug Details: Saxenda, known chemically as liraglutide, is a first-generation GLP-1 drug that helps curb appetite and control blood sugar levels.
Market Position: Teva's generic version is the first GLP-1 drug approved for weight loss in the U.S., although it results in less weight loss compared to Novo's newer treatment, Wegovy.
Target Population: Saxenda is approved for use in obese adults with weight-related medical issues and adolescents aged 12 to 17 who weigh over 60 kg and have obesity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
